<DOC>
	<DOC>NCT02544789</DOC>
	<brief_summary>Outcomes for children with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) are dismal. Therefore, the investigators performed this multicenter, phase II study to evaluate the efficacy and , safety and pharmacokinetic of clofarabine in Chinese pediatric patients with R/R ALL</brief_summary>
	<brief_title>Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>Pediatric patients (younger than 21 years old) with acute lymphoblastic leukemia confirmed by histology Refractory or relapsed acute lymphocytic leukemia who had received at least two drugs treatment No prior chemotherapy within 2 weeks before entry and resolution of toxic effects from prior therapy Normal cardiac function, adequate hepatic function [total bilirubin ≤1.5× upper limit of normal (ULN), aspartate aminotransferase (AST) alanine aminotransferase (ALT) ≤ 3ULN] and renal function (serum creatinine ≤ 2 ULN) Eastern Cooperative Oncology Group (ECOG) performance status 02 Life expectancy more than 3 months AEs not recovered from prior therapy Within 3 months from allogeneic or autologous stem cell transplantation With central nervous involvement or uncontrolled infection Patients who used clofarabine before or allergic to fludarabine or cladribine</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>